Loading…
Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients
The association between body mass index (BMI) and the overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients remains controversial and unclear, METHOD: A total of 2010 patients from a high-volume center were enrolled in the study. The OS of PDAC patients was evaluated based on res...
Saved in:
| Published in: | BMC cancer 2021-12, Vol.21 (1), p.1318-1318, Article 1318 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c527t-63bde5406ac55059b2a850cb93454c75ad392db2163104646e45af403570cd283 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c527t-63bde5406ac55059b2a850cb93454c75ad392db2163104646e45af403570cd283 |
| container_end_page | 1318 |
| container_issue | 1 |
| container_start_page | 1318 |
| container_title | BMC cancer |
| container_volume | 21 |
| creator | Fu, Ningzhen Jiang, Yu Qin, Kai Chen, Hao Deng, Xiaxing Shen, Baiyong |
| description | The association between body mass index (BMI) and the overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients remains controversial and unclear, METHOD: A total of 2010 patients from a high-volume center were enrolled in the study. The OS of PDAC patients was evaluated based on restricted cubic spline (RCS), propensity score (PS) and multivariable risk adjustment analyses.
BMI was linearly related to the OS (total P = 0.004, nonlinear P = 0.124). BMI was analyzed as categorical data based on X-tile software-defined cutoffs and World Health Organization (WHO)-recommended cutoffs. Adjusted with confounding covariates, higher BMI manifested as a positive prognostic predictor. Furthermore, BMI was proven to be associated with the OS in the PS analysis. (Underweight
vs. Normal
P = 0.003, Overweight
vs. Normal
P = 0.019; Underweight
vs. Normal
P |
| doi_str_mv | 10.1186/s12885-021-09056-0 |
| format | article |
| fullrecord | <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_2b19a7e3ec904ceba9a71147b6384f86</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A686425203</galeid><doaj_id>oai_doaj_org_article_2b19a7e3ec904ceba9a71147b6384f86</doaj_id><sourcerecordid>A686425203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c527t-63bde5406ac55059b2a850cb93454c75ad392db2163104646e45af403570cd283</originalsourceid><addsrcrecordid>eNpdkk1vEzEQhlcIREvhD3BAlpAQl4Xx53o5VKoqoJUqcYGzNWs7iaPNOtjeQP8Cvxo3KVHLxR_jZ17PjN6meU3hA6VafcyUaS1bYLSFHqRq4UlzSkVHWyage_rgfNK8yHkNQDsN-nlzwoXWSgM9bf5cheXKJzJEd0s2mDMJk_O_79ZgsXhHBl9KBeLOJxxHkue0CzscK0G2ONnksQRL3GxLDaLzU7SYbJjiBitQgp9K_kSQVHBsf8U0OpLLXH-LC8KAwhF62Txb4Jj9q_v9rPnx5fP3y6v25tvX68uLm9ZK1pVW8cF5KUChlRJkPzDUEuzQcyGF7SQ63jM3MKo4BaGE8kLiQgCXHVjHND9rrg-6LuLabFPYYLo1EYPZB2JaGky1p9EbNtAeO8-97UFYP2C90TrVQXEtFlpVrfOD1nYeNt7Z2ked0iPRxy9TWJll3BmtpALWVYH39wIp_px9LmYTsvXjiJOPczZMgZac9fu63_6HruOcpjqqSlHKKe85q9S7A7XE2sCqDr2schznEuKUzYXSSjDJgFeQHUCbYs7JL45VUzB3_jIHf5nqL7P3l4Ga9OZhv8eUf4bifwHKrst7</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2611313932</pqid></control><display><type>article</type><title>Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Fu, Ningzhen ; Jiang, Yu ; Qin, Kai ; Chen, Hao ; Deng, Xiaxing ; Shen, Baiyong</creator><creatorcontrib>Fu, Ningzhen ; Jiang, Yu ; Qin, Kai ; Chen, Hao ; Deng, Xiaxing ; Shen, Baiyong</creatorcontrib><description>The association between body mass index (BMI) and the overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients remains controversial and unclear, METHOD: A total of 2010 patients from a high-volume center were enrolled in the study. The OS of PDAC patients was evaluated based on restricted cubic spline (RCS), propensity score (PS) and multivariable risk adjustment analyses.
BMI was linearly related to the OS (total P = 0.004, nonlinear P = 0.124). BMI was analyzed as categorical data based on X-tile software-defined cutoffs and World Health Organization (WHO)-recommended cutoffs. Adjusted with confounding covariates, higher BMI manifested as a positive prognostic predictor. Furthermore, BMI was proven to be associated with the OS in the PS analysis. (Underweight
vs. Normal
P = 0.003, Overweight
vs. Normal
P = 0.019; Underweight
vs. Normal
P < 0.001, Overweight
vs. Normal
P = 0.024). It was also revealed that patients with higher BMI benefitted more from chemotherapy. (Adjusted hazard ratio (aHR): Underweight
vs. Normal
vs. Overweight
: 0.565 vs. 0.474 vs. 0.409; Underweight
vs. Normal
vs. Overweight
: 0.613 vs. 0.464 vs. 0.425).
Among PDAC patients, there was a positive association between BMI and the OS, especially in patients treated with chemotherapy.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-021-09056-0</identifier><identifier>PMID: 34886801</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adenocarcinoma ; Aged ; Analysis ; Antineoplastic Agents - therapeutic use ; Body Mass Index ; Body mass index (BMI). Pancreatic ductal adenocarcinoma (PDAC). Overall survival (OS). Restricted cubic spline (RCS). Chemotherapy ; Carcinoma, Pancreatic Ductal - epidemiology ; Carcinoma, Pancreatic Ductal - mortality ; Care and treatment ; Chemotherapy ; Female ; Humans ; Male ; Medical prognosis ; Metastasis ; Middle Aged ; Overweight ; Overweight - epidemiology ; Pancreas ; Pancreatic cancer ; Pancreatic Neoplasms ; Pancreatic Neoplasms - epidemiology ; Pancreatic Neoplasms - mortality ; Prognosis ; Retrospective Studies ; Statistics ; Survival ; Survival analysis ; Thinness - epidemiology ; Variables</subject><ispartof>BMC cancer, 2021-12, Vol.21 (1), p.1318-1318, Article 1318</ispartof><rights>2021. The Author(s).</rights><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c527t-63bde5406ac55059b2a850cb93454c75ad392db2163104646e45af403570cd283</citedby><cites>FETCH-LOGICAL-c527t-63bde5406ac55059b2a850cb93454c75ad392db2163104646e45af403570cd283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656027/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2611313932?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34886801$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fu, Ningzhen</creatorcontrib><creatorcontrib>Jiang, Yu</creatorcontrib><creatorcontrib>Qin, Kai</creatorcontrib><creatorcontrib>Chen, Hao</creatorcontrib><creatorcontrib>Deng, Xiaxing</creatorcontrib><creatorcontrib>Shen, Baiyong</creatorcontrib><title>Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>The association between body mass index (BMI) and the overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients remains controversial and unclear, METHOD: A total of 2010 patients from a high-volume center were enrolled in the study. The OS of PDAC patients was evaluated based on restricted cubic spline (RCS), propensity score (PS) and multivariable risk adjustment analyses.
BMI was linearly related to the OS (total P = 0.004, nonlinear P = 0.124). BMI was analyzed as categorical data based on X-tile software-defined cutoffs and World Health Organization (WHO)-recommended cutoffs. Adjusted with confounding covariates, higher BMI manifested as a positive prognostic predictor. Furthermore, BMI was proven to be associated with the OS in the PS analysis. (Underweight
vs. Normal
P = 0.003, Overweight
vs. Normal
P = 0.019; Underweight
vs. Normal
P < 0.001, Overweight
vs. Normal
P = 0.024). It was also revealed that patients with higher BMI benefitted more from chemotherapy. (Adjusted hazard ratio (aHR): Underweight
vs. Normal
vs. Overweight
: 0.565 vs. 0.474 vs. 0.409; Underweight
vs. Normal
vs. Overweight
: 0.613 vs. 0.464 vs. 0.425).
Among PDAC patients, there was a positive association between BMI and the OS, especially in patients treated with chemotherapy.</description><subject>Adenocarcinoma</subject><subject>Aged</subject><subject>Analysis</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Body Mass Index</subject><subject>Body mass index (BMI). Pancreatic ductal adenocarcinoma (PDAC). Overall survival (OS). Restricted cubic spline (RCS). Chemotherapy</subject><subject>Carcinoma, Pancreatic Ductal - epidemiology</subject><subject>Carcinoma, Pancreatic Ductal - mortality</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Overweight</subject><subject>Overweight - epidemiology</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - epidemiology</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Statistics</subject><subject>Survival</subject><subject>Survival analysis</subject><subject>Thinness - epidemiology</subject><subject>Variables</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1vEzEQhlcIREvhD3BAlpAQl4Xx53o5VKoqoJUqcYGzNWs7iaPNOtjeQP8Cvxo3KVHLxR_jZ17PjN6meU3hA6VafcyUaS1bYLSFHqRq4UlzSkVHWyage_rgfNK8yHkNQDsN-nlzwoXWSgM9bf5cheXKJzJEd0s2mDMJk_O_79ZgsXhHBl9KBeLOJxxHkue0CzscK0G2ONnksQRL3GxLDaLzU7SYbJjiBitQgp9K_kSQVHBsf8U0OpLLXH-LC8KAwhF62Txb4Jj9q_v9rPnx5fP3y6v25tvX68uLm9ZK1pVW8cF5KUChlRJkPzDUEuzQcyGF7SQ63jM3MKo4BaGE8kLiQgCXHVjHND9rrg-6LuLabFPYYLo1EYPZB2JaGky1p9EbNtAeO8-97UFYP2C90TrVQXEtFlpVrfOD1nYeNt7Z2ked0iPRxy9TWJll3BmtpALWVYH39wIp_px9LmYTsvXjiJOPczZMgZac9fu63_6HruOcpjqqSlHKKe85q9S7A7XE2sCqDr2schznEuKUzYXSSjDJgFeQHUCbYs7JL45VUzB3_jIHf5nqL7P3l4Ga9OZhv8eUf4bifwHKrst7</recordid><startdate>20211209</startdate><enddate>20211209</enddate><creator>Fu, Ningzhen</creator><creator>Jiang, Yu</creator><creator>Qin, Kai</creator><creator>Chen, Hao</creator><creator>Deng, Xiaxing</creator><creator>Shen, Baiyong</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PIMPY</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20211209</creationdate><title>Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients</title><author>Fu, Ningzhen ; Jiang, Yu ; Qin, Kai ; Chen, Hao ; Deng, Xiaxing ; Shen, Baiyong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c527t-63bde5406ac55059b2a850cb93454c75ad392db2163104646e45af403570cd283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenocarcinoma</topic><topic>Aged</topic><topic>Analysis</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Body Mass Index</topic><topic>Body mass index (BMI). Pancreatic ductal adenocarcinoma (PDAC). Overall survival (OS). Restricted cubic spline (RCS). Chemotherapy</topic><topic>Carcinoma, Pancreatic Ductal - epidemiology</topic><topic>Carcinoma, Pancreatic Ductal - mortality</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Overweight</topic><topic>Overweight - epidemiology</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - epidemiology</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Statistics</topic><topic>Survival</topic><topic>Survival analysis</topic><topic>Thinness - epidemiology</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fu, Ningzhen</creatorcontrib><creatorcontrib>Jiang, Yu</creatorcontrib><creatorcontrib>Qin, Kai</creatorcontrib><creatorcontrib>Chen, Hao</creatorcontrib><creatorcontrib>Deng, Xiaxing</creatorcontrib><creatorcontrib>Shen, Baiyong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Health & Medical Collection</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fu, Ningzhen</au><au>Jiang, Yu</au><au>Qin, Kai</au><au>Chen, Hao</au><au>Deng, Xiaxing</au><au>Shen, Baiyong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2021-12-09</date><risdate>2021</risdate><volume>21</volume><issue>1</issue><spage>1318</spage><epage>1318</epage><pages>1318-1318</pages><artnum>1318</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>The association between body mass index (BMI) and the overall survival (OS) of pancreatic ductal adenocarcinoma (PDAC) patients remains controversial and unclear, METHOD: A total of 2010 patients from a high-volume center were enrolled in the study. The OS of PDAC patients was evaluated based on restricted cubic spline (RCS), propensity score (PS) and multivariable risk adjustment analyses.
BMI was linearly related to the OS (total P = 0.004, nonlinear P = 0.124). BMI was analyzed as categorical data based on X-tile software-defined cutoffs and World Health Organization (WHO)-recommended cutoffs. Adjusted with confounding covariates, higher BMI manifested as a positive prognostic predictor. Furthermore, BMI was proven to be associated with the OS in the PS analysis. (Underweight
vs. Normal
P = 0.003, Overweight
vs. Normal
P = 0.019; Underweight
vs. Normal
P < 0.001, Overweight
vs. Normal
P = 0.024). It was also revealed that patients with higher BMI benefitted more from chemotherapy. (Adjusted hazard ratio (aHR): Underweight
vs. Normal
vs. Overweight
: 0.565 vs. 0.474 vs. 0.409; Underweight
vs. Normal
vs. Overweight
: 0.613 vs. 0.464 vs. 0.425).
Among PDAC patients, there was a positive association between BMI and the OS, especially in patients treated with chemotherapy.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>34886801</pmid><doi>10.1186/s12885-021-09056-0</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2021-12, Vol.21 (1), p.1318-1318, Article 1318 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_2b19a7e3ec904ceba9a71147b6384f86 |
| source | Publicly Available Content (ProQuest); PubMed Central |
| subjects | Adenocarcinoma Aged Analysis Antineoplastic Agents - therapeutic use Body Mass Index Body mass index (BMI). Pancreatic ductal adenocarcinoma (PDAC). Overall survival (OS). Restricted cubic spline (RCS). Chemotherapy Carcinoma, Pancreatic Ductal - epidemiology Carcinoma, Pancreatic Ductal - mortality Care and treatment Chemotherapy Female Humans Male Medical prognosis Metastasis Middle Aged Overweight Overweight - epidemiology Pancreas Pancreatic cancer Pancreatic Neoplasms Pancreatic Neoplasms - epidemiology Pancreatic Neoplasms - mortality Prognosis Retrospective Studies Statistics Survival Survival analysis Thinness - epidemiology Variables |
| title | Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-03-06T04%3A05%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Higher%20body%20mass%20index%20indicated%20better%20overall%20survival%20in%20pancreatic%20ductal%20adenocarcinoma%20patients:%20a%20real-world%20study%20of%202010%20patients&rft.jtitle=BMC%20cancer&rft.au=Fu,%20Ningzhen&rft.date=2021-12-09&rft.volume=21&rft.issue=1&rft.spage=1318&rft.epage=1318&rft.pages=1318-1318&rft.artnum=1318&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-021-09056-0&rft_dat=%3Cgale_doaj_%3EA686425203%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c527t-63bde5406ac55059b2a850cb93454c75ad392db2163104646e45af403570cd283%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2611313932&rft_id=info:pmid/34886801&rft_galeid=A686425203&rfr_iscdi=true |